FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092507930> ?p ?o ?g. }

• W2092507930 endingPage "176" @default.
• W2092507930 startingPage "169" @default.
• W2092507930 abstract "This randomized multicenter phase III trial evaluated the role of maintenance therapy with pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation. Time to progression (TTP) was the primary endpoint. 288 patients were enrolled and received induction first-line chemotherapy. One hundred and fifty-five achieved response or stable disease and were randomized to maintenance PLD (n = 78) or observation (n = 77). With a median follow-up of 20 months from randomization (range 1–56), disease progression occurred in 94% of patients. PLD significantly improved TTP by 3.3 months (8.4 vs. 5.1 months; hazard ratio [HR] = 0.54, 95% CI: 0.39 to 0.76, P = 0.0002) compared with observation. Overall survival was not significantly prolonged with PLD (24.8 vs. 22.0 months, respectively; HR = 0.86, 95% CI: 0.58–1.27, P = 0.44). PLD-induced toxicity was mild and manageable with up to 5% of patients experiencing grade 3/4 non-hematologic events (fatigue, mucositis, palmar-plantar erythrodysesthesia). Grade 3/4 neutropenia occurred in 12% of patients; two patients developed febrile neutropenia. This phase III trial demonstrated that maintenance chemotherapy with PLD is well tolerated and offers improved TTP in patients with MBC following first-line chemotherapy." @default.
• W2092507930 created "2016-06-24" @default.
• W2092507930 creator A5019586191 @default.
• W2092507930 creator A5020462811 @default.
• W2092507930 creator A5029469753 @default.
• W2092507930 creator A5035054317 @default.
• W2092507930 creator A5036532311 @default.
• W2092507930 creator A5045301167 @default.
• W2092507930 creator A5046655410 @default.
• W2092507930 creator A5049908989 @default.
• W2092507930 creator A5058463933 @default.
• W2092507930 creator A5064901053 @default.
• W2092507930 creator A5071202334 @default.
• W2092507930 creator A5075417603 @default.
• W2092507930 creator A5080310093 @default.
• W2092507930 creator A5087468615 @default.
• W2092507930 creator A5089006820 @default.
• W2092507930 date "2010-04-02" @default.
• W2092507930 modified "2023-10-06" @default.
• W2092507930 title "Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study" @default.
• W2092507930 cites W1688680124 @default.
• W2092507930 cites W1966943069 @default.
• W2092507930 cites W1967484801 @default.
• W2092507930 cites W1987684534 @default.
• W2092507930 cites W1999982168 @default.
• W2092507930 cites W2008778169 @default.
• W2092507930 cites W2019415608 @default.
• W2092507930 cites W2039356896 @default.
• W2092507930 cites W2084130216 @default.
• W2092507930 cites W2096593771 @default.
• W2092507930 cites W2101742864 @default.
• W2092507930 cites W2121794314 @default.
• W2092507930 cites W2135828743 @default.
• W2092507930 cites W2148845753 @default.
• W2092507930 cites W2158448509 @default.
• W2092507930 cites W2256705735 @default.
• W2092507930 cites W2327116942 @default.
• W2092507930 cites W2391957425 @default.
• W2092507930 cites W4234943217 @default.
• W2092507930 cites W4240696126 @default.
• W2092507930 doi "https://doi.org/10.1007/s10549-010-0860-9" @default.
• W2092507930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20361253" @default.
• W2092507930 hasPublicationYear "2010" @default.
• W2092507930 type Work @default.
• W2092507930 sameAs 2092507930 @default.
• W2092507930 citedByCount "64" @default.
• W2092507930 countsByYear W20925079302012 @default.
• W2092507930 countsByYear W20925079302013 @default.
• W2092507930 countsByYear W20925079302014 @default.
• W2092507930 countsByYear W20925079302015 @default.
• W2092507930 countsByYear W20925079302016 @default.
• W2092507930 countsByYear W20925079302017 @default.
• W2092507930 countsByYear W20925079302018 @default.
• W2092507930 countsByYear W20925079302019 @default.
• W2092507930 countsByYear W20925079302020 @default.
• W2092507930 countsByYear W20925079302021 @default.
• W2092507930 countsByYear W20925079302022 @default.
• W2092507930 crossrefType "journal-article" @default.
• W2092507930 hasAuthorship W2092507930A5019586191 @default.
• W2092507930 hasAuthorship W2092507930A5020462811 @default.
• W2092507930 hasAuthorship W2092507930A5029469753 @default.
• W2092507930 hasAuthorship W2092507930A5035054317 @default.
• W2092507930 hasAuthorship W2092507930A5036532311 @default.
• W2092507930 hasAuthorship W2092507930A5045301167 @default.
• W2092507930 hasAuthorship W2092507930A5046655410 @default.
• W2092507930 hasAuthorship W2092507930A5049908989 @default.
• W2092507930 hasAuthorship W2092507930A5058463933 @default.
• W2092507930 hasAuthorship W2092507930A5064901053 @default.
• W2092507930 hasAuthorship W2092507930A5071202334 @default.
• W2092507930 hasAuthorship W2092507930A5075417603 @default.
• W2092507930 hasAuthorship W2092507930A5080310093 @default.
• W2092507930 hasAuthorship W2092507930A5087468615 @default.
• W2092507930 hasAuthorship W2092507930A5089006820 @default.
• W2092507930 hasBestOaLocation W20925079302 @default.
• W2092507930 hasConcept C121608353 @default.
• W2092507930 hasConcept C126322002 @default.
• W2092507930 hasConcept C141071460 @default.
• W2092507930 hasConcept C143998085 @default.
• W2092507930 hasConcept C168563851 @default.
• W2092507930 hasConcept C203092338 @default.
• W2092507930 hasConcept C207103383 @default.
• W2092507930 hasConcept C2775930923 @default.
• W2092507930 hasConcept C2776611710 @default.
• W2092507930 hasConcept C2776694085 @default.
• W2092507930 hasConcept C2777063308 @default.
• W2092507930 hasConcept C2778496288 @default.
• W2092507930 hasConcept C2778850193 @default.
• W2092507930 hasConcept C2781190966 @default.
• W2092507930 hasConcept C2781303535 @default.
• W2092507930 hasConcept C44249647 @default.
• W2092507930 hasConcept C530470458 @default.
• W2092507930 hasConcept C71924100 @default.
• W2092507930 hasConcept C90924648 @default.
• W2092507930 hasConceptScore W2092507930C121608353 @default.
• W2092507930 hasConceptScore W2092507930C126322002 @default.
• W2092507930 hasConceptScore W2092507930C141071460 @default.
• W2092507930 hasConceptScore W2092507930C143998085 @default.
• W2092507930 hasConceptScore W2092507930C168563851 @default.

• next